CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 1651-A |

# Specialty Guideline Management sildenafil-Revatio-Liqrev

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Revatio | sildenafil |
| Liqrev | sildenafil |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-Approved Indications1-4

* Revatio/Liqrev/sildenafil is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening.
* Revatio/sildenafil is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underly improvements in exercise.

### Compendial Uses

* Secondary Raynaud’s phenomenon8,9
* PAH (WHO Group I) in pediatric members less than 1 year of ageA

All other indications are considered experimental/investigational and not medically necessary.

## Prescriber Specialties

This medication must be prescribed by or in consultation with a pulmonologist or cardiologist for the diagnosis of pulmonary arterial hypertension (PAH).

## Coverage Criteria

### Pulmonary Arterial Hypertension (PAH)1-4,14,17-19

Authorization of 12 months may be granted for treatment of PAH when ALL of the following criteria are met:

* Member has PAH defined as WHO Group 1 class of pulmonary hypertension (refer to Appendix).
* PAH was confirmed by either of the following criteria:
  + Pretreatment right heart catheterization with all of the following results:
    - Mean pulmonary arterial pressure (mPAP) > 20 mmHg
    - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
    - Pulmonary vascular resistance (PVR) > 2 Wood units. For pediatric members, pulmonary vascular resistance index (PVRI) > 3 Wood units x m2 is also acceptable.
  + For infants less than one year of age, PAH was confirmed by Doppler echocardiogram if right heart catheterization cannot be performed.

### Secondary Raynaud’s Phenomenon8-13

Authorization of 12 months may be granted for treatment of secondary Raynaud’s phenomenon when the member has had an inadequate response to one of the following medications:

* Calcium channel blockers
* Angiotensin II receptor blockers
* Selective serotonin reuptake inhibitors
* Alpha blockers
* Angiotensin-converting enzyme inhibitors
* Topical nitrates

## Continuation of Therapy

Authorization of 12 months may be granted for members with an indication listed in the coverage criteria section who are currently receiving the requested medication through a paid pharmacy or medical benefit, and who are experiencing benefit from therapy as evidenced by disease stability or disease improvement.

## Appendix

### WHO Classification of Pulmonary Hypertension (PH)17

Note: Patients with heritable PAH or PAH associated with drugs and toxins might be long-term responders to calcium channel blockers.

#### Group 1: Pulmonary Arterial Hypertension (PAH)

* Idiopathic
  + Long-term responders to calcium channel blockers
* Heritable
* Associated with drugs and toxins
* Associated with:
  + Connective tissue disease
  + Human immunodeficiency virus (HIV) infection
  + Portal hypertension
  + Congenital heart disease
  + Schistosomiasis
* PAH with features of venous/capillary (pulmonary veno-occlusive disease [PVOD]/pulmonary capillary hemangiomatosis [PCH]) involvement
* Persistent PH of the newborn

#### Group 2: PH associated with Left Heart Disease

* Heart failure:
  + With preserved ejection fraction
  + With reduced or mildly reduced ejection fraction
  + Cardiomyopathies with specific etiologies (i.e., hypertrophic, amyloid, Fabry disease, and Chagas disease)
* Valvular heart disease:
  + Aortic valve disease
  + Mitral valve disease
  + Mixed valvular disease
* Congenital/acquired cardiovascular conditions leading to post-capillary PH

#### Group 3: PH associated with Lung Diseases and/or Hypoxia

* Chronic obstructive pulmonary disease (COPD) and/or emphysema
* Interstitial lung disease
* Combined pulmonary fibrosis and emphysema
* Other parenchymal lung diseases (i.e., parenchymal lung diseases not included in Group 5)
* Nonparenchymal restrictive diseases:
  + Hypoventilation syndromes
  + Pneumonectomy
* Hypoxia without lung disease (e.g., high altitude)
* Developmental lung diseases

#### Group 4: PH associated with Pulmonary Artery Obstructions

* Chronic thromboembolic PH
* Other pulmonary artery obstructions:
  + Sarcomas (high- or intermediate-grade or angiosarcoma)
  + Other malignant tumors (e.g., renal carcinoma, uterine carcinoma, germ-cell tumors of the testis)
  + Non-malignant tumors (e.g., uterine leiomyoma)
  + Arteritis without connective tissue disease
  + Congenital pulmonary artery stenoses
  + Hydatidosis

#### Group 5: PH with Unclear and/or Multifactorial Mechanisms

* Hematological disorders, including inherited and acquired chronic hemolytic anemia and chronic myeloproliferative disorders
* Systemic disorders: Sarcoidosis, pulmonary Langerhans cell histiocytosis, and neurofibromatosis type 1
* Metabolic disorders, including glycogen storage diseases and Gaucher disease
* Chronic renal failure with or without hemodialysis
* Pulmonary tumor thrombotic microangiopathy
* Fibrosing mediastinitis
* Complex congenital heart disease

## References

1. Revatio [package insert]. Morgantown, WV; Viatris Specialty LLC; October 2024.
2. Liqrev [package insert]. Farmville, NC: CMP Pharma, Inc.; April 2023.
3. Sildenafil tablet [package insert]. Basking Ridge, NJ: Torrent Pharma INC., Inc.; November 2024.
4. Sildenafil powder for oral suspension [package insert]. Parsippany, NJ: Ascend Laboratories, LLC; September 2023.
5. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naïve children with pulmonary arterial hypertension. Circulation. 2012;125:324-334.
6. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157.
7. Rubin LJ, Badesch DB, Fleming RT, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension. Chest. 2011;140(5):1274-1283.
8. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com. Accessed November 20, 2024.
9. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. Accessed November 20, 2024.
10. Hughes M, Ong VH, Anderson ME, et al. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology. 2015;54:2015-2024.
11. Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomized trials. Ann Rheum Dis. 2013;72(10):1696-1699.
12. Walker KM, Pope J, et al. Treatment of systemic sclerosis complications: what to use when first-line treatment fails – a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42(1):42-55.
13. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339.
14. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. doi: 10.1183/13993003.01913-2018
15. Barst RJ, Beghetti M, Pulido T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014;129(19):1914-23.
16. Kwan WC, Shavelle DM, Laughrun DR. Pulmonary vascular resistance index: getting the units right and why it matters. Clin Cardiol. 2019;42(3):334-338.
17. Kovacs G, Bartolome S, Denton CP, et al. Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. 2024;64(4):2401324. doi: 10.1183/13993003.01324-2024
18. Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401325. doi: 10.1183/13993003.01325-2024
19. Ivy D, Rosenzweig EB, Abman SH, et al. Embracing the challenges of neonatal and paediatric pulmonary hypertension. Eur Respir J. 2024;64(4):2401345. doi: 10.1183/13993003.01345-2024